DHRS11 (dehydrogenase/reductase 11) is a short-chain dehydrogenase/reductase family member that catalyzes multiple steroid metabolic reactions. Enzymatically, DHRS11 converts the 17-keto group of estrone and androgens into 17β-hydroxyl metabolites and reduces 3-keto groups of diketosteroids into 3β-hydroxyl forms, using NADPH as a coenzyme 1. Notably, DHRS11 reduces 11-keto-androgen precursors (11-keto-4-androstene-3,17-dione and 11-keto-5α-androstane-3,17-dione) into potent androgens 11-ketotestosterone and 11-ketodihydrotestosterone 2. The enzyme also metabolizes α-dicarbonyl compounds and alicyclic ketones 1. DHRS11 expression is widely distributed across tissues, with highest levels in testis, small intestine, colon, and kidney 1. Clinically, DHRS11 has emerged as a therapeutic target in multiple diseases. Genetic studies identified DHRS11 as a causal mediator for both amyotrophic lateral sclerosis and multiple sclerosis risk 34. In luminal androgen receptor-positive triple-negative breast cancer, DHRS11 inhibition suppresses androgen-driven proliferation and enhances sensitivity to AKT inhibitors 5. DHRS11 was also identified as a programmed cell death-associated hub gene in heart failure with diagnostic and prognostic significance 6. These findings position DHRS11 as a multifunctional enzyme with relevance to steroid metabolism, neurodegeneration, and cancer biology.